Daniela Alberati
Overview
Explore the profile of Daniela Alberati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinard E, Borroni E, Koerner A, Umbricht D, Alberati D
Chimia (Aarau)
. 2018 Aug;
72(7):477-484.
PMID: 30158010
Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical companies and academic institutions primarily as a potential new approach to treat schizophrenia, a severe and chronic mental illness....
2.
Vengeliene V, Rossmanith M, Takahashi T, Alberati D, Behl B, Bespalov A, et al.
J Pharmacol Exp Ther
. 2018 Jan;
365(1):202-211.
PMID: 29367277
It has recently been demonstrated that pharmacological blockade of the glycine transporter 1 (GlyT1) reduced alcohol intake and relapse in rats. The aim of the present study was to further...
3.
Yohn S, Alberati D, Correa M, Salamone J
Psychopharmacology (Berl)
. 2017 Jan;
234(9-10):1525-1534.
PMID: 28083675
Rationale: Motivated behavior can be characterized by a substantial exertion of effort, and organisms often make effort-related decisions based upon analyses of work-related response costs and reinforcement preference. Moreover, alterations...
4.
Winter M, Funk J, Korner A, Alberati D, Christen F, Schmitt G, et al.
Exp Hematol
. 2016 Jul;
44(10):964-974.e4.
PMID: 27403535
Glycine is a key rate-limiting component of heme biosynthesis in erythropoietic cells, where the high intracellular glycine demand is primarily supplied by the glycine transporter 1 (GlyT1). The impact of...
5.
Barrow P, Parrott N, Alberati D, Paehler A, Koerner A
Birth Defects Res B Dev Reprod Toxicol
. 2016 May;
107(3):148-56.
PMID: 27221585
Bitopertin is a glycine type 1 (GlyT1) inhibitor intended for the treatment of psychiatric disorders. The principle adverse effect in the regulatory reproductive toxicity studies was peri-natal pup death when...
6.
Hofmann C, Pizzagalli F, Boetsch C, Alberati D, Ereshefsky L, Jhee S, et al.
Psychopharmacology (Berl)
. 2016 May;
233(13):2429-39.
PMID: 27178435
Rationale: Hypofunction of NMDA receptors has been implicated in neuropsychiatric disorders including schizophrenia. NMDA receptor neurotransmission can be enhanced through inhibition of glycine reuptake by the glycine transporter type 1...
7.
Goonawardena A, Heiss J, Glavis-Bloom C, Trube G, Borroni E, Alberati D, et al.
Neuropsychopharmacology
. 2015 Sep;
41(5):1319-28.
PMID: 26354045
A growing body of evidence indicates that neuronal oscillations in the gamma frequency range (30-80 Hz) are disturbed in schizophrenic patients during cognitive processes and may represent an endophenotype of...
8.
Pinard E, Alberati D, Alvarez-Sanchez R, Brom V, Burner S, Fischer H, et al.
ACS Med Chem Lett
. 2014 Jun;
5(4):428-33.
PMID: 24900853
3-Amido-3-aryl-piperidines were discovered as a novel structural class of GlyT1 inhibitors. The structure-activity relationship, which was developed, led to the identification of highly potent compounds exhibiting excellent selectivity against the...
9.
Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef E, Ostland M, et al.
JAMA Psychiatry
. 2014 Apr;
71(6):637-46.
PMID: 24696094
Importance: In schizophrenia, the severity of negative symptoms is a key predictor of long-term disability. Deficient signaling through the N-methyl-D-aspartate receptor is hypothesized to underlie many signs and symptoms associated...
10.
Parrott N, Hainzl D, Alberati D, Hofmann C, Robson R, Boutouyrie B, et al.
Clin Pharmacokinet
. 2013 Apr;
52(8):673-83.
PMID: 23591780
Background: Bitopertin (RG1678) is a glycine reuptake inhibitor currently in phase 3 trials for treatment of schizophrenia. This paper describes the use of physiologically based pharmacokinetic (PBPK) modelling and preclinical...